No Data
Despite Delivering Investors Losses of 25% Over the Past 3 Years, Shanghai Kaibao PharmaceuticalLtd (SZSE:300039) Has Been Growing Its Earnings
Shanghai Kaibao Pharmaceutical (300039.SZ) currently has no production of anticancer drugs.
Gelonghui, March 19 - Shanghai Kaibao Pharmaceutical (300039.SZ) stated on the investor interaction platform that the company currently has no production of anticancer drugs. The products of its affiliated company, Shanghai Yizhong, belong to the oncology field.
Shanghai Kaibao Pharmaceutical (300039.SZ): Subsidiary obtained the pharmaceutical registration certificate for Doxofylline Tablets.
Gelonghui, March 10: Shanghai Kaibao Pharmaceutical (300039.SZ) announced that its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd. has recently received the "Drug Registration Certificate" for Doxofylline tablets issued by the National Medical Products Administration. Doxofylline tablets are suitable for bronchial asthma, wheezing chronic bronchitis, and other respiratory difficulties caused by bronchospasm. According to inquiries, as of now, this Pharmaceutical has only been approved for registration and marketing of generic drugs by this enterprise and is regarded as having passed the consistency evaluation.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Should Weakness in Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Shanghai Kaibao Pharmaceutical (300039.SZ): Linggui Zhugan Decoction granules have completed pharmaceutical registration.
Shanghai Kaibao Pharmaceutical (300039.SZ) announced that the company recently received the approval from the National Medical Products Administration for Linggui Zhugan Decoction...
The Market Doesn't Like What It Sees From Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Earnings Yet